+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Dasatinib-induced pulmonary arterial hypertension - A rare late complication



Dasatinib-induced pulmonary arterial hypertension - A rare late complication



Journal of Oncology Pharmacy Practice 2018: 1078155217753740



Dasatinib is a dual Src/Abl tyrosine kinase inhibitor approved for frontline and second line treatment of chronic phase chronic myelogenous leukemia. Pulmonary arterial hypertension is defined by an increase in mean pulmonary arterial pressure >25 mmHg at rest. Dasatinib-induced pulmonary hypertension has been reported in less than 1% of patients on chronic dasatinib treatment for chronic myelogenous leukemia. The pulmonary arterial hypertension from dasatinib may be categorized as either group 1 (drug-induced) or group 5 based on various mechanisms that may be involved including the pathogenesis of the disease process of chronic myelogenous leukemia. There have been reports of dasatinib-induced pulmonary arterial hypertension being reversible. We report a case of pulmonary arterial hypertension in a 46-year-old female patient with chronic phase chronic myelogenous leukemia on dasatinib treatment for over 10 years. She had significant improvement in symptoms after discontinuation of dasatinib and initiation of vasodilators. Several clinical questions arise once patients experience significant adverse effects as discussed in our case.

(PDF emailed within 0-6 h: $19.90)

Accession: 057523078

Download citation: RISBibTeXText

PMID: 29343154

DOI: 10.1177/1078155217753740


Related references

Dasatinib-induced pulmonary arterial hypertension. British Journal of Clinical Pharmacology 84(5): 835-845, 2018

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. European Respiratory Journal 51(3), 2018

Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. European Respiratory Journal 42(3): 869-870, 2014

Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension. International Journal of Cardiovascular Imaging 2019, 2019

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy. Case Reports in Cardiology 2018: 3895197, 2018

Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report. European Heart Journal. Case Reports 3(1): Ytz025, 2019

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal 50(1), 2018

Pulmonary arterial hypertension: A rare yet fatal complication of Neurofibromatosis Type 1. Respiratory Medicine Case Reports 27: 100832, 2019

Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. Chest 138(2): 461-2; Author Reply 462-3, 2010

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. Pulmonary Circulation 7(4): 803-807, 2017

Pulmonary arterial hypertension and right heart failure--a late-onset complication after cardiac catheterization. Catheterization and Cardiovascular Interventions 73(7): 979-981, 2009

Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine 86(5): 299-315, 2007

Late-onset pulmonary arterial hypertension in repaired D-transposition of great arteries: an uncommon complication. Pulmonary Circulation 7(2): 547-550, 2017

Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17): 2128-2137, 2012

Dasatinib: pulmonary arterial hypertension. French data. Prescrire International 20(120): 241-241, 2011